Palivizumab: A debate about funding
Author:
Publisher
Wiley
Subject
Pediatrics, Perinatology, and Child Health
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1440-1754.2010.01865.x/fullpdf
Reference12 articles.
1. Development of a humanised monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus;Johnson;J. Infect. Dis.,1997
2. Safety, tolerance and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group;Subramanian;Pediatr. Infect. Dis.,1998
3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduced hospitalization from respiratory syncytial virus infection in high risk infants;Impact-RSV Study Group;Pediatrics,1998
4. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with haemodynamically significant congenital heart disease;Feltes;J. Pediatr.,2003
5. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab;Fitzgerald;Paediatr. Respir. Rev.,2009
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bronchopulmonary dysplasia: A review of the pulmonary sequelae in the post‐surfactant era;Journal of Paediatrics and Child Health;2020-04-08
2. Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis;The Journal of Pediatrics;2019-11
3. Good Practices and Principles in Health Technology Assessment in Latin America;Value in Health Regional Issues;2018-12
4. A population study of respiratory rehospitalisation in very preterm infants in the first 3 years of life;Journal of Paediatrics and Child Health;2016-05-20
5. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus? The case against;Paediatric Respiratory Reviews;2013-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3